None listed
Conditions
Brief summary
Study hypothesis: Following an acute exposure to strength training exercise and nutritional supplementation with whey protein, limbs with a history of ACL injury will demonstrate increased activation of key molecular pathways underlying muscle growth, compared to a placebo-supplemented control group. A double-blinded two-conditions crossover design. Following an acute exposure to strength training exercise and nutritional supplementation with whey protein, limbs with a history of ACL injury will demonstrate increased activation of key molecular pathways underlying muscle growth, compared to a placebo-supplemented control group. Participants will be randomly assigned a trial order with each trial separated by a period of at least 5 days. All participants will first undergo magnetic resonance imaging (MRI) to assess quadriceps muscle size (i.e., volume) in both legs and preliminary resistance exercise testing to determine maximal strength of each leg. The design of the two experimental trials will follow the same format, with at least 5 days separating each. The evening prior to each experimental trial, participants will be provided a standardised meal to consume and be asked to arrive to the laboratory after an overnight fast (~8-10h). A small (i.e., ~150 mg) resting muscle biopsy sample will be obtained from the outer quadriceps (vastus lateralis) of the previously injured and contralateral (non-injured) limbs under local anaesthesia and sterile conditions. Additionally, a small blood sample (12mL each) will be collected pre, 1-hour and 3-hours post exercise for each of the two experimental trials, with a total of 6 blood samples collected over the entire study period. Immediately following the resting muscle biopsy collection, participants will consume approximately 0.4g/kg body weight whey protein isolate or an isocaloric placebo. After approximately 15 minutes of recovery after sample collection, participants will perform 6 sets of 8 unilateral leg-press repetitions with both limbs (90 second rest between sets) at a resistance equivalent to 80% of their unilateral maximum strength (determined for both legs independently). Participants will consume either a whey protein supplement or placebo immediately post exercise. 1 hour and 3 hours following completion of exercise, a subsequent biopsy will be obtained from the vastus lateralis muscle of each leg.
Interventions
Magnetic Resonance Imaging (MRI) scans will be completed using a 3Tesla imaging system. Muscle volume of all lower limb muscles will be determined for both limbs using an automated segmentation platform at the beginning of the trial, prior to intervention. MRI Scans will be performed during each participant’s familiarisation visit, prior to nutrition and exercise interventions. Each participant will undergo a single MRI of both lower limbs that will take 30 minutes in total. Participants will be escorted to Swinburne Neuroimaging by research staff, with MRIs supervised by an experienced radiographer at Swinburne Neuroimaging (Swinburne University). The evening prior to each experimental trial, participants will be provided a standardised meal to consume and be asked to arrive to the laboratory after an overnight fast (~8-10h). Participants will receive their standardised meal following their MRI at Swinburne University, comprised of chicken breast tenders/canned tuna/tofu, steam fresh carrot, cauliflower & broccoli, medium grain brown rice and butter. Each participant will undergo unilateral leg-press 1 repetition maximum (1RM) testing once only, at their initial familiarisation visit, following their MRI. 1RM will be determined for both the injured and uninjured limb. A single 1RM test will be performed, supervised by trained research staff. Each limb will complete a warm up with load equivalent to 5 on a 10 rating of perceived exertion scale for 3-5 repetitions. Load will incrementally increase (by approx 5-20kg) and repetitions will decrease until the load an individual cannot successfully lift for 1 repetition is found. 1RM testing will take approximately 15 minutes to complete. 12 muscle biopsies in total will be obtained per participant; 1 pre exercise biopsy and 1-hour post exercise, and 3-hours post exercise from each leg. This will be repeated for each of the two supplement conditions (whey protein or placebo). Additionally, 6 small blood samples (12mL each) will be collected, pre and 1-hour and 3-hours post exercise for each of the two supplement conditions. Supplementation: Immediately following leg press exercises, participants will consume 0.4g/kg body weight of whey protein isolate or an isocaloric placebo. Acute strength training intervention: Acute strength training will commence 15 minutes after resting muscle biopsies. Participants will complete a warm up of 10 reps on each leg with no load, before commencing the strength training intervention. In total, the intervention will run for 30 minutes, supervised by trained research staff. All participants will perform 6-8 sets of 8 repetitions of unilateral leg press exercise with load equivalent to 80% 1RM for each leg. Each set will be completed 1 leg at a time with limbs completing sets in alternating order. Each limb will be given 90sec rest between sets. Shortly after the final muscle biopsy sampling and completion of experimental exercise session participants will be offered a light snack (e.g. muesli bar). The washout period between each intervention will be no more than one week between experimental conditions.
Sponsors
Study design
Eligibility
Inclusion criteria
Male or female Aged between 18 to 40 years One leg sustained an ACL injury within the last 2-years, but the participant can safely complete lower limb strength training.
Exclusion criteria
ACL injury without surgical reconstruction Any lower limb injury in the past 24-months that influences the quadriceps responses to exercise (e.g. muscle strain) Known cardiovascular disease or diabetes Known bleeding disorder (i.e. hemophilia A [factor VIII deficiency], hemophilia B [factor IX deficiency], von Willebrand disease, or other rare factor deficiencies including I, II, V, VII, X, XI, XII and XIII) Major or chronic illness that impairs mobility or eating/digestion Taking prescription medications (i.e. beta-blockers, anti-arrhythmic drugs, statins, insulin sensitising drugs, or drugs that increase the risk of bleeding [i.e. anticoagulants, antiplatelets, novel oral anticoagulants [NOAs], nonsteroidal anti-inflammatory drugs [NSAIDs], selective norepinephrine reuptake inhibitors [SNRI], or selective serotonin reuptake inhibitors [SSRIs]) Any contraindications to MRI assessed via the Swinburne Neuroimaging MRI Safety Questionnaire and Consent Form. Individuals with allergy/intolerance to milk and/or milk products.